Kyle Piskel - 28 Nov 2025 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
Chief Financial Officer
Signature
/s/ Kyle Piskel
Issuer symbol
ADPT
Transactions as of
28 Nov 2025
Net transactions value
-$1,921,449
Form type
4
Filing time
02 Dec 2025, 18:45:03 UTC
Previous filing
18 Nov 2025
Next filing
14 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PISKEL KYLE Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE /s/ Kyle Piskel 02 Dec 2025 0001780662

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $78,469 +11,980 +4.4% $6.55 281,323 28 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $29,250 +3,750 +1.3% $7.80 285,073 28 Nov 2025 Direct F1
transaction ADPT Common Stock Options Exercise $1,145,822 +94,384 +33% $12.14 379,457 28 Nov 2025 Direct F1
transaction ADPT Common Stock Sale $3,174,990 -162,820 -43% $19.50 216,637 28 Nov 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (right to buy) Options Exercise $0 -11,980 -100% $0.000000 0 28 Nov 2025 Common Stock 11,980 $6.55 Direct F1, F3
transaction ADPT Stock Option (right to buy) Options Exercise $0 -3,750 -100% $0.000000 0 28 Nov 2025 Common Stock 3,750 $7.80 Direct F1, F3
transaction ADPT Stock Option (right to buy) Options Exercise $0 -94,384 -92% $0.000000 8,581 28 Nov 2025 Common Stock 94,384 $12.14 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.
F2 The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $19.28 to $19.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The option is fully vested and exercisable.
F4 The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.